SEARCH

SEARCH BY CITATION

References

  • Baquero MR, Nilsson AI, Turrientes Mdel C, Sandvang D, Galan JC, Martinez JL, Frimodt-Moller N, Baquero F & Andersson DI (2004) Polymorphic mutation frequencies in Escherichia coli: emergence of weak mutators in clinical isolates. J Bacteriol 186: 55385542.
  • Blazquez J (2003) Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 37: 12011209.
  • Chopra I, O'Neill AJ & Miller K (2003) The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat 6: 137145.
  • Clinical and Laboratory Standards Institute (CLSI) (2008) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Test for Bacteria Isolated from Animals; Approved Standard – Third Edition. CLSI Document M31-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
  • Clinical and Laboratory Standards Institute (CLSI) (2011) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. CLSI Document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
  • Cremonesi P, Luzzana M, Brasca M, Morandi S, Lodi R, Vimercati C, Agnellini D, Caramenti G, Moroni P & Castiglioni B (2005) Development of a multiplex PCR assay for the identification of Staphylococcus aureus enterotoxigenic strains isolated from milk and dairy products. Mol Cell Probes 19: 299305.
  • Denamur E & Matic I (2006) Evolution of mutation rates in bacteria. Mol Microbiol 60: 820827.
  • Giraud A, Matic I, Tenaillon O, Clara A, Radman M, Fons M & Taddei F (2001) Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 291: 26062608.
  • Giraud A, Matic I, Radman M, Fons M & Taddei F (2002) Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 46: 863865.
  • Hall LM & Henderson-Begg SK (2006) Hypermutable bacteria isolated from humans - a critical analysis. Microbiology 152: 25052514.
  • Hooper DC (2002) Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2: 530538.
  • Horst JP, Wu TH & Marinus MG (1999) Escherichia coli mutator genes. Trends Microbiol 7: 2936.
  • Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA & Hooper DC (2009) Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother 53: 639645.
  • Le Gall S, Desbordes L, Gracieux P, Saffroy S, Bousarghin L, Bonnaure-Mallet M & Jolivet-Gougeon A (2009) Distribution of mutation frequencies among Salmonella enterica isolates from animal and human sources and genetic characterization of a Salmonella Heidelberg hypermutator. Vet Microbiol 137: 306312.
  • Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL & Oliver A (2005) Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49: 33823386.
  • Oliver A, Canton R, Campo P, Baquero F & Blazquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288: 12511254.
  • Oliver A, Baquero F & Blazquez J (2002) The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol 43: 16411650.
  • Orlen H & Hughes D (2006) Weak mutators can drive the evolution of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 50: 34543456.
  • Prunier AL & Leclercq R (2005) Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus. J Bacteriol 187: 34553464.
  • Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF & Leclercq R (2003) High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187: 17091716.
  • Robicsek A, Jacoby GA & Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 6: 629640.
  • Schmitz FJ, Jones ME, Hofmann B et al. (1998) Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother 42: 12491252.
  • Schmitz FJ, Higgins PG, Mayer S, Fluit AC & Dalhoff A (2002) Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis 21: 647659.
  • Shaver AC, Dombrowski PG, Sweeney JY, Treis T, Zappala RM & Sniegowski PD (2002) Fitness evolution and the rise of mutator alleles in experimental Escherichia coli populations. Genetics 162: 557566.
  • Strahilevitz J, Jacoby GA, Hooper DC & Robicsek A (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22: 664689.
  • Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH & Godelle B (1997) Role of mutator alleles in adaptive evolution. Nature 387: 700702.
  • Trong HN, Prunier AL & Leclercq R (2005) Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 49: 20982101.
  • Turrientes MC, Turrientes MC, Baquero MR et al. (2010) Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. Appl Environ Microbiol 76: 17461758.
  • Wang T, Tanaka M & Sato K (1998) Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother 42: 236240.
  • Wang M, Guo Q, Xu X, Wang X, Ye X, Wu S & Hooper DC (2009) New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 53: 18921897.